InvestorsHub Logo
Followers 30
Posts 5054
Boards Moderated 0
Alias Born 01/07/2020

Re: None

Wednesday, 08/12/2020 2:46:03 PM

Wednesday, August 12, 2020 2:46:03 PM

Post# of 425933
Some positive energy from Yahoo - thanks to Robert.

robert yesterday

Amara - Inept management: really?

expanded label approval in Dec 2019 - yes only 9 months ago (with 6 of those months during the Covid crisis)
800 person sales force in trained and in place
growing revenues even during the Covid crisis in spite
cash balance net of debt - $600 million
cash flow positive
went + on earnings this Q
Approved in Canada with partner in place
European approval in the 4th Q 2020
Evaporate results upcoming in 3rd Q
3 separate trials for Vascepa to treat Covid
NASH pII run by Gilead complete - waiting for results
cancer trial
China approval likely in 2021
Already have a fantastic partner in place in China - Edding Pharma
AND we still own 100% of USA and European rights

And BTW, do you really think AMRN would go it alone in Europe without positive Evaporate data? I don't

I guess you prefer a management team that manages the share price instead of the business.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News